Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 0.80 |
| ▸ | CRBN | Q96SW2 | 18/20 | 0.80 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381751 | 0.92 | DDB1 (0.76) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2382628 | 0.90 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12250746 | 0.89 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12250735 | 0.89 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29922319 | 0.89 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL502014 | 0.89 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3783402 | 0.89 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL5136914 | 0.88 | DDB1 (0.83) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2382415 | 0.87 | DDB1 (0.81) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL476960 | 0.87 | DDB1 (0.81) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919892-B1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2013-08-14 | — | — | EP | claimed |
| US-7964354-B2 | Use of micro-RNA as a biomarker of immunomodulatory drug activity | CELGENE CORPORATION (US) | 2011-06-21 | — | — | US | claimed |
| US-20090176237-A1 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION | 2009-07-09 | — | — | US | claimed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | claimed |
| EP-3904875-B1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | CELGENE CORP (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3313818-B1 | METHODS FOR THE TREATMENT OF KAPOSI'S SARCOMA OR KSHV-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS, AND USES OF BIOMARKERS | CELGENE CORP (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2022-08-23 | — | — | US | disclosed |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CELGENE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220026439-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences BV (BE) | 2022-01-27 | — | — | US | disclosed |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORPORATION (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3077548-B1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORP (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3904875-A1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | Celgene Corporation (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2009085234-A2 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | SIGNAL PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090148853-A1 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORPORATION | 2009-06-11 | — | — | US | disclosed |
| CN-101291924-A | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORP (US) | 2008-10-22 | — | — | CN | disclosed |
| EP-1919892-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027527-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | DDB1 247/4885CRBN 1/4885IKZF3 1204/4885 |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | BCL9, BCL9L, IKZF1 | DDB1 52/4885CRBN 5/4885IKZF3 4/4885 |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CD79B, BCL6, CD22 | DDB1 378/4885CRBN 401/4885IKZF3 107/4885 |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | SI, CYP3A5, CYP2D6 | DDB1 4509/4885CRBN 2589/4885IKZF3 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.